TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma

Liyona Kampel; Sara Feldstein; Shlomo Tsuriel; Leonor Leider Trejo; Gilad Horowitz; Anton Warshavsky; Jobran Mansour; Dov Hershkovitz; Nidal Muhanna

doi:10.1016/j.radonc.2025.110714

TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma

Radiother Oncol. 2025 Jan 10:110714. doi: 10.1016/j.radonc.2025.110714. Online ahead of print.

Authors

Liyona Kampel¹, Sara Feldstein², Shlomo Tsuriel², Leonor Leider Trejo², Gilad Horowitz³, Anton Warshavsky³, Jobran Mansour³, Dov Hershkovitz², Nidal Muhanna⁴

Affiliations

¹ The Head and Neck Cancer Research Laboratory, Tel Aviv, Israel; The Department of Otolaryngology, Head and Neck Surgery and Maxillofacial Surgery, Tel Aviv, Israel.
² The Cancer Research and Pathology Institute, and Tel Aviv Sourasky Medical Center, Tel Aviv, Israel(1).
³ The Department of Otolaryngology, Head and Neck Surgery and Maxillofacial Surgery, Tel Aviv, Israel.
⁴ The Head and Neck Cancer Research Laboratory, Tel Aviv, Israel; The Department of Otolaryngology, Head and Neck Surgery and Maxillofacial Surgery, Tel Aviv, Israel. Electronic address: [email protected].

PMID: 39800270
DOI: 10.1016/j.radonc.2025.110714

Abstract

Head and neck squamous cell carcinomas (HNSCC) frequently recur, and patients often develop second primary tumors. Their distinction is clinically challenging. TP53 mutational heterogeneity may indicate novel molecular events rather than resistant clones' expansion or persistent disease. Surveillance and therapeutic strategies should be adjusted, especially in the case of a second primary arising in an already irradiated field.

Keywords: Head and neck squamous cell carcinoma; Irradiation; Recurrence; TP53.